In early January MaaT Pharma made waves in the pharma world with the announcement of positive topline results for their phase 3 trial of MaaT013 in acute Graft-versus-Host Disease. With robust efficacy and safety data, […]
MaaT Pharma (EURONEXT: MAAT – the “Company”), a late-stage clinical-stage biotechnology company leading the development of Microbiome Ecosystem Therapies TM (MET) to improve survival in cancer patients through modulation of the immune system, today announced topline results from […]
Following the announcement of Lallemand’s new R&D laboratories in France, Microbiome Times caught up with Sylvie Binda, VP of R&D to discuss the company’s goals and objectives. Can you elaborate on how the new laboratories […]
Eczema and Atopic Dermatitis (AD) is thought to affect as many as 10% of adults worldwide and represents a debilitating condition for many.1 It can result in a lower quality of life, and reports link […]
Next-generation sequencing (NGS) represents an innovative and versatile technology for microbial identification and characterization. NGS offers flexibility to scale methods based on the experimental interest. Widely available NGS methods include amplicon sequencing, hybrid capture, whole-genome […]
Have you considered analyzing captured breath to uncover the secrets of microbial metabolism? In this interview, we speak to Dr Liz Crone, Head of Business Development, Research Products & Services for Europe and Asia at breath-based […]
Microbiome Times Magazine, the microbiome industry’s leading B2B publication, is pleased to announce its collaboration with the coalition groups European Microbiome Innovation for Health (EMIH) and Microbiome Therapeutics Innovation Group (MTIG) for its upcoming Microbiome […]
Reusing data collected in clinical studies is of strong scientific and economic interest. Anonymisation has emerged as a solution to extend data life, while providing regulatory compliance and privacy protection. Nevertheless, true anonymisation of complex […]
Three patent claims, one present in each of three US patents held by the Finch Therapeutics Group Inc. (Finch), have been found to have been infringed by Ferring Pharmaceuticals Inc.’s (Ferring) activities in the US […]
Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, publishes a landmark study in Nature that unlocks Genome Editing of Bacteria in the Gut. […]
ISB microbiome researchers have shown that microbial community-scale metabolic modeling can predict personalized short-chain-fatty-acid production profiles in the human gut. Their findings were published in the journal Nature Microbiology. Short-chain fatty acids (SCFAs) are beneficial […]